Role of IHC in Diagnosis of Soft Tissue Tumors

1. Why IHC is Needed

• Many tumors share similar histologic patterns (e.g., spindle cell pattern in DFSP, MPNST, synovial sarcoma, leiomyosarcoma)
• Small biopsy material limits full architectural assessment
• Grade and subtype carry direct prognostic and therapeutic implications

2. General Lineage Markers

3. IHC for Specific Tumor Types

Lipomatous Tumors / Liposarcoma

• The histologic hallmark is the lipoblast, but IHC and molecular studies are needed for subclassification
• MDM2 and CDK4 IHC: both well-differentiated and dedifferentiated liposarcomas show strong nuclear positivity (due to amplification of chromosome 12q13-15 containing MDM2 and CDKN4)
• Adipophilin: expressed in lipoblasts, helpful as a supplementary marker
• FISH for MDM2/CDK4 amplification is confirmatory when IHC is positive
• Sabiston Textbook of Surgery, p. 2821: "Both well-differentiated and dedifferentiated liposarcomas can be distinguished from lipomas and other poorly differentiated STS subtypes on the basis of MDM2 and CDK4 immunohistochemistry."

Fibroblastic / Myofibroblastic Tumors

• DFSP (Dermatofibrosarcoma Protuberans): strongly CD34-positive spindle cells; the related giant cell fibroblastoma also reacts with anti-CD34 antibodies and shares t(17;22) translocation
• Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma: IHC shows strong MUC4 expression (associated with FUS-CREB3L2 or EWSR1-CREB3L1 fusions)
• Myxofibrosarcoma: diagnosis based on morphology; no specific IHC marker
• Dermatology 2-Volume Set 5e, Table 116.4

Ewing Sarcoma / PNET

• Morphology: sheets of small round blue cells, +/- Homer-Wright rosettes
• IHC: CD99 (membranous, diffuse) - highly sensitive but not specific
• FLI1 nuclear expression - correlates with EWSR1-FLI1 fusion t(11;22)
• PNET (neuroendocrine variant) shows additional neuroendocrine markers (synaptophysin, NSE)
• Molecular confirmation with FISH or RT-PCR for EWSR1 rearrangement is gold standard
• Henry's Clinical Diagnosis, p. 1307

Clear Cell Sarcoma (Melanoma of Soft Parts)

• Melanocytic differentiation despite arising in soft tissues
• IHC: S-100, HMB-45, Melan-A - same as conventional melanoma
• Molecular distinction from melanoma: t(12;22)(q13;q13) producing EWSR1-ATF1 fusion
• Henry's Clinical Diagnosis, p. 1312

Synovial Sarcoma

• Biphasic (epithelial + spindle) or monophasic (spindle only)
• IHC: cytokeratin (AE1/AE3, CAM5.2) focal+, EMA focal+, TLE1 (nuclear, highly sensitive and specific), CD99 variable
• SS18-SSX fusion gene (t(X;18)) detected by FISH or RT-PCR is confirmatory

MPNST (Malignant Peripheral Nerve Sheath Tumor)

• IHC: S-100 (focal, 50-70%), SOX10 (more sensitive), H3K27me3 loss (marker of aggressive behavior and PRC2 complex inactivation in NF1-associated MPNST)
• CD34 negative (helps distinguish from DFSP)

Rhabdomyosarcoma

• IHC panel: desmin, myogenin, MyoD1 (nuclear) - nuclear myogenin/MyoD1 are most specific for skeletal muscle differentiation
• Alveolar subtype: PAX3-FOXO1 or PAX7-FOXO1 fusion (FISH)

Gastrointestinal Stromal Tumor (GIST)

• IHC: KIT (CD117) - strongly positive (95%), DOG1 (TMEM16A, anoctamin 1) - highly specific, CD34 positive in most
• KIT/PDGFRA mutation analysis guides targeted therapy (imatinib)

4. IHC in Small Round Cell Tumors - Differential Panel

5. IHC for Lineage Assignment in Spindle Cell Tumors

6. IHC in Dermatopathology (Skin/Subcutaneous Soft Tissue Tumors)

• Vimentin: all mesenchymal cell types (screening)
• S-100: melanocytic tumors, neural tumors (Schwannoma, neurofibroma)
• CD34: vascular tumors, DFSP
• Desmin: smooth and skeletal muscle tumors
• HMB-45 / Melan-A / MiTF: melanocytic differentiation (clear cell sarcoma vs melanoma)
• CK20: Merkel cell carcinoma (small round cell tumor of skin, distinct from PNET)
• Dermatology 2-Volume Set 5e, Table 0.13

7. Limitations of IHC

• No single marker is 100% specific - panels are always used
• Fixation artifacts and antigen retrieval failures can cause false negatives
• Focal/weak positivity must be interpreted in context
• IHC cannot replace molecular/cytogenetic testing for definitive classification of translocation-associated sarcomas (Ewing, synovial sarcoma, DFSP, etc.)
• Pleomorphic/dedifferentiated sarcomas often lose lineage-specific markers

8. IHC + Molecular Integration

Summary

1. Lineage identification (muscle, neural, vascular, fibroblastic, epithelioid)
2. Differential diagnosis within spindle cell or round cell morphologic groups
3. Subtype-specific confirmation (e.g., MDM2/CDK4 for liposarcoma, CD99/FLI1 for Ewing)
4. Surrogate for molecular events (e.g., TLE1 for SS18-SSX, MUC4 for FUS fusions)
5. Prognostic information (e.g., H3K27me3 loss in MPNST)

• Sabiston Textbook of Surgery, 21e, Soft Tissue Sarcomas chapter
• Dermatology 2-Volume Set 5e (Bolognia), Chapters 116-117 (fibroblastic sarcomas, liposarcomas)
• Henry's Clinical Diagnosis and Management by Laboratory Methods, Ewing Sarcoma and Clear Cell Sarcoma sections
• Harrison's Principles of Internal Medicine 22e, Role of Pathologic Studies in cancer of unknown primary